** Shares of genetic testing firm Natera NTRA.O rise 2.7% to $281.85

** Co says its personalized cancer test, Signatera, received certification under the European Union's diagnostic device rules

** Signatera is used to detect traces of cancer that may remain after treatment and monitor for recurrence

** Co says Signatera is the first personalized residual-disease test for solid tumors to receive this EU certification

** Certification covers use across several cancers, including gastrointestinal, lung, breast, skin, gynecological and some blood cancers - NTRA

** NTRA says the certification will help it continue offering Signatera to EU patients after the 2028 regulatory transition deadline and reduce hurdles for launching new clinical trials

** Including session's move, NTRA up 22% YTD